KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) Net Income towards Common Stockholders: 2009-2025

Historic Net Income towards Common Stockholders for Regeneron Pharmaceuticals (REGN) over the last 17 years, with Sep 2025 value amounting to $1.5 billion.

  • Regeneron Pharmaceuticals' Net Income towards Common Stockholders rose 8.91% to $1.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.6 billion, marking a year-over-year decrease of 1.64%. This contributed to the annual value of $4.4 billion for FY2024, which is 11.61% up from last year.
  • Regeneron Pharmaceuticals' Net Income towards Common Stockholders amounted to $1.5 billion in Q3 2025, which was up 4.92% from $1.4 billion recorded in Q2 2025.
  • In the past 5 years, Regeneron Pharmaceuticals' Net Income towards Common Stockholders registered a high of $3.1 billion during Q2 2021, and its lowest value of $722.0 million during Q1 2024.
  • Its 3-year average for Net Income towards Common Stockholders is $1.1 billion, with a median of $1.0 billion in 2023.
  • Per our database at Business Quant, Regeneron Pharmaceuticals' Net Income towards Common Stockholders skyrocketed by 245.36% in 2021 and then slumped by 72.50% in 2022.
  • Over the past 5 years, Regeneron Pharmaceuticals' Net Income towards Common Stockholders (Quarterly) stood at $2.2 billion in 2021, then tumbled by 46.29% to $1.2 billion in 2022, then fell by 3.13% to $1.2 billion in 2023, then fell by 20.86% to $917.7 million in 2024, then climbed by 8.91% to $1.5 billion in 2025.
  • Its last three reported values are $1.5 billion in Q3 2025, $1.4 billion for Q2 2025, and $808.7 million during Q1 2025.